Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA and "street drug alternatives"

This article was originally published in The Tan Sheet

Executive Summary

Agency will announce the availability of an industry guidance on "street drug alternatives" in the April 3 Federal Register. The guidance outlines FDA's policy concerning products manufactured or marketed as alternatives to illicit street drugs, stating any such item is "an unapproved new drug and a misbranded drug in violation of sections 505 and 502 of the [FD&C] Act" and such violations may result in "seizure and injunction." FDA also notes many of these products are "labeled as containing botanicals...[or] vitamins, minerals or amino acids," while others "are being marketed as dietary supplements." However, because street drug alternatives are not "intended to supplement the diet," FDA maintains they do not fall under this regulatory category. Copies of the guidance will be available at www.fda.gov/cder/guidance/index.htm; comments may be submitted to the agency at any time
Advertisement

Related Content

Supplements Sold As “Street Drug Alternatives” Draw FDA Warning Letters
Supplements Sold As “Street Drug Alternatives” Draw FDA Warning Letters
Supplements Sold As “Street Drug Alternatives” Draw FDA Warning Letters
Ephedrine Alkaloid Weight-Loss Claims Proposed Ban Lifted By FDA
Ephedrine Alkaloid Weight-Loss Claims Proposed Ban Lifted By FDA
Ephedrine Alkaloid Weight-Loss Claims Proposed Ban Lifted By FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS091035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel